drugset
drugset / Trial / NCT06148389

The Safety and Tolerability of STSA-1301 Subcutaneous Injection in Healthy Subjects

NCT06148389 ↗

Phase 1 Completed 36 enrolled Staidson (Beijing) Biopharmaceuticals Co., Ltd
RandomizedSequentialQuadruple-blindTreatment

Summary

A randomized, double-blind, placebo-controlled, single-ascending dose, phase Ia study to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamics, and immunogenicity of STSA-1301 Subcutaneous Injection in healthy subjects.

Timeline

Start
2023-11-16
Primary completion
2024-04-03
Completion
2024-04-03

Drugs

EvaluationDrugModalityDoseRoute
Subject STSA-1301 Unknown — Subcutaneous

Indications

primary thrombocytopenia